Use of β-lactam/β-lactamase inhibitors for extended-spectrum-β-lactamase infections: defining the right patient population
β-Lactam/β-lactamase inhibitors (BLBLIs) were compared to carbapenems in two cohorts of hematological neutropenic patients with extended-spectrum-β-lactamase (ESBL) bloodstream infection (BSI): the empirical therapy cohort (174 patients) and the definitive therapy cohort (251 patients). The 30-day c...
| Autores: | , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2017 |
| País: | Colombia |
| Institución: | Universidad El Bosque |
| Repositorio: | Repositorio U. El Bosque |
| Idioma: | inglés |
| OAI Identifier: | oai:repositorio.unbosque.edu.co:20.500.12495/3503 |
| Acceso en línea: | http://hdl.handle.net/20.500.12495/3503 https://doi.org/10.1128/AAC.01094-17 https://repositorio.unbosque.edu.co |
| Access Level: | acceso abierto |
| Palabra clave: | Beta-Lactamas Inhibidores de beta-Lactamasas Carbapenémicos ESBLs Bloodstream infection Neutropenia |
| Sumario: | β-Lactam/β-lactamase inhibitors (BLBLIs) were compared to carbapenems in two cohorts of hematological neutropenic patients with extended-spectrum-β-lactamase (ESBL) bloodstream infection (BSI): the empirical therapy cohort (174 patients) and the definitive therapy cohort (251 patients). The 30-day case fatality rates and other secondary outcomes were similar in the two therapy groups of the two cohorts and also in the propensity-matched cohorts. BLBLIs might be carbapenem-sparing alternatives for the treatment of BSI due to ESBLs in these patients. |
|---|